Figure 1.
Figure 1. TRM and LFS in patients with acute and chronic leukemia after BM and PBSC transplantation. (A) Cumulative incidence of TRM in patients with acute leukemia after BM and PBSC transplantation adjusted for disease status at transplantation (n, number of evaluable patients; %, the 6-year rate of TRM). (B) Cumulative incidence of TRM in patients with chronic leukemia after BM and PBSC transplantation adjusted for disease status at transplantation (n, number of evaluable patients; %, 6-year rate of TRM). (C) Probability of LFS in patients with acute leukemia after BM and PBSC transplantation adjusted for disease status at transplantation (n, number of evaluable patients; %, 6-year rate of LFS). (D) Probability of LFS in patients with chronic leukemia after BM and PBSC transplantation adjusted for disease status at transplantation (n, number of evaluable patients; %, 6-year rate of LFS).

TRM and LFS in patients with acute and chronic leukemia after BM and PBSC transplantation. (A) Cumulative incidence of TRM in patients with acute leukemia after BM and PBSC transplantation adjusted for disease status at transplantation (n, number of evaluable patients; %, the 6-year rate of TRM). (B) Cumulative incidence of TRM in patients with chronic leukemia after BM and PBSC transplantation adjusted for disease status at transplantation (n, number of evaluable patients; %, 6-year rate of TRM). (C) Probability of LFS in patients with acute leukemia after BM and PBSC transplantation adjusted for disease status at transplantation (n, number of evaluable patients; %, 6-year rate of LFS). (D) Probability of LFS in patients with chronic leukemia after BM and PBSC transplantation adjusted for disease status at transplantation (n, number of evaluable patients; %, 6-year rate of LFS).

Close Modal
This Feature Is Available To Subscribers Only

or Create an Account

Close Modal
Close Modal